Exenatide-Associated Ischemic Renal Failure
Year: 2009
Type: article
Study design: Case Report
Abstract: Exenatide is a synthetic peptide that belongs to a new class of antidiabetes agents known as incretin mimetics. Like the endogenous incretin hormone glucagon-like peptide 1 (GLP-1), exenatide effectively lowers blood glucose levels by stimulating insulin release, inhibiting glucagon secretion, and delaying gastric emptying. Nausea and vomiting are the most common adverse reactions, which lead to discontinuation in as many as 14% of patients in one study (1).
We report on four patients (three male and one female; age 52–73 years) with exenatide-associated renal failure who presented with nausea, vomiting, or decreased fluid intake. All patients had type 2 diabetes with or without mild microalbuminuria and hypertension. They were taking …
Source: Diabetes Care
DOI: 10.2337/dc08-1309
Authors: Wolfgang J. Weise, Mala S. Sivanandy, Clay A. Block, Richard J. Comi
Institutions: University of Vermont, Dartmouth–Hitchcock Medical Center
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1971478725
